Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 2/20 | 0.57 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.53 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504303 | 0.82 | ATR (0.57) | PRKCIALDH1A1GAAATR | |
| SCHEMBL5682288 | 0.82 | ATR (0.57) | PRKCIALDH1A1GAAATR | |
| SCHEMBL3405233 | 0.81 | CDK5 (0.57) | PRKCIF7F3SARM1SIRT2 | |
| SCHEMBL3409177 | 0.80 | ALDH1A1 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL3409170 | 0.80 | NAPRT (0.56) | PRKCIF7F3SARM1SIRT2 | |
| SCHEMBL29915528 | 0.78 | ALDH1A1 (0.71) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL1242243 | 0.78 | ALDH1A1 (0.71) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL14324877 | 0.78 | SIRT2 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL27841975 | 0.76 | ALDH1A1 (0.68) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL27669301 | 0.75 | PRKCI (0.50) | PRKCIATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| CN-102036961-B | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2014-02-26 | — | — | CN | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| CN-102036961-A | Pyridine and pyrazine compounds as PI3K inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | PRKCI 3911/4885F7 964/4885F3 482/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | PRKCI 3911/4885F7 964/4885F3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.